Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

Inclusion criteria

• ✓. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
• ✓. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
• ✓. Patients with vitiligo or alopecia
• ✓. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
• ✓. Any chronic skin condition that does not require systemic therapy
• ✓. Patients without active disease in the last 5 years may be included but only after consultation with the study physician
• ✓. Patients with celiac disease controlled by diet alone
• ✓. Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence